Monthly information on share capital and company voting
(Article 223-16 of General Regulation of the French financial markets authority)...
Stay updated with breaking news from Allogeneic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
(Article 223-16 of General Regulation of the French financial markets authority)...
A single-center cohort analysis showed the biosimilar provided similar PBSC mobilization to originator filgrastim.
Learn about the successful adult allogeneic bone marrow transplant performed at Zulekha Yenepoya Institute of Oncology. Find out how a 40-year-old man with relapsed acute myeloid leukaemia underwent a haploidentical transplant and recovered with minimal complications.
Poseida is a clinical-stage biotechnology company dedicated to advancing a new class of cancer cell therapy and gene therapy products using genetic engineering technologies Astellas to invest a total of $50 million to acquire approximately 8.8% of Poseida and to receive a right of exclusive negotiation and first refusal for any potential partnering of P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy product candidate for solid tumors Astellas will have the right to designate an obser...
78% Overall Response Rate (14/18 patients), including seven patients exhibiting a complete response to TT11X allogeneic CAR-T therapySafety data...